A citation-based method for searching scientific literature

Alberto Chiarugi. Trends Pharmacol Sci 2012
Times Cited: 32







List of co-cited articles
271 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
71

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
65

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
37

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
34

Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
Ponnari Gottipati, Barbara Vischioni, Niklas Schultz, Joyce Solomons, Helen E Bryant, Tatjana Djureinovic, Natalia Issaeva, Kate Sleeth, Ricky A Sharma, Thomas Helleday. Cancer Res 2010
160
31

Resistance to therapy caused by intragenic deletion in BRCA2.
Stacey L Edwards, Rachel Brough, Christopher J Lord, Rachael Natrajan, Radost Vatcheva, Douglas A Levine, Jeff Boyd, Jorge S Reis-Filho, Alan Ashworth. Nature 2008
700
31

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Junko Murai, Shar-yin N Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier. Cancer Res 2012
31


53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.
Samuel F Bunting, Elsa Callén, Nancy Wong, Hua-Tang Chen, Federica Polato, Amanda Gunn, Anne Bothmer, Niklas Feldhahn, Oscar Fernandez-Capetillo, Liu Cao,[...]. Cell 2010
28

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.
Peter Bouwman, Amal Aly, Jose M Escandell, Mark Pieterse, Jirina Bartkova, Hanneke van der Gulden, Sanne Hiddingh, Maria Thanasoula, Atul Kulkarni, Qifeng Yang,[...]. Nat Struct Mol Biol 2010
682
28

PARP inhibition: PARP1 and beyond.
Michèle Rouleau, Anand Patel, Michael J Hendzel, Scott H Kaufmann, Guy G Poirier. Nat Rev Cancer 2010
936
25

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
Ana M Mendes-Pereira, Sarah A Martin, Rachel Brough, Afshan McCarthy, Jessica R Taylor, Jung-Sik Kim, Todd Waldman, Christopher J Lord, Alan Ashworth. EMBO Mol Med 2009
478
25

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Karen A Gelmon, Marc Tischkowitz, Helen Mackay, Kenneth Swenerton, André Robidoux, Katia Tonkin, Hal Hirte, David Huntsman, Mark Clemons, Blake Gilks,[...]. Lancet Oncol 2011
821
25

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Wataru Sakai, Elizabeth M Swisher, Beth Y Karlan, Mukesh K Agarwal, Jake Higgins, Cynthia Friedman, Emily Villegas, Céline Jacquemont, Daniel J Farrugia, Fergus J Couch,[...]. Nature 2008
712
25

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Peter C Fong, Timothy A Yap, David S Boss, Craig P Carden, Marja Mergui-Roelvink, Charlie Gourley, Jacques De Greve, Jan Lubinski, Susan Shanley, Christina Messiou,[...]. J Clin Oncol 2010
687
25

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
25

Poly(ADP-ribose): novel functions for an old molecule.
Valérie Schreiber, Françoise Dantzer, Jean-Christophe Ame, Gilbert de Murcia. Nat Rev Mol Cell Biol 2006
21

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O H Nygren, Serge A L Zander, Patrick W B Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau,[...]. Proc Natl Acad Sci U S A 2008
673
21

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Katherine M Bell-McGuinn, Clare Scott, Jeffrey N Weitzel, Ana Oaknin, Niklas Loman,[...]. Lancet 2010
999
21

Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
Louise J Barber, Shahneen Sandhu, Lina Chen, James Campbell, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, Daniel Nava Rodrigues, Jorge S Reis Filho, Victor Moreno,[...]. J Pathol 2013
222
21

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Janneke E Jaspers, Ariena Kersbergen, Ute Boon, Wendy Sol, Liesbeth van Deemter, Serge A Zander, Rinske Drost, Ellen Wientjens, Jiuping Ji, Amal Aly,[...]. Cancer Discov 2013
339
21

Mechanisms of resistance to therapies targeting BRCA-mutant cancers.
Christopher J Lord, Alan Ashworth. Nat Med 2013
283
21

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
Nuala McCabe, Nicholas C Turner, Christopher J Lord, Katarzyna Kluzek, Aneta Bialkowska, Sally Swift, Sabrina Giavara, Mark J O'Connor, Andrew N Tutt, Małgorzata Z Zdzienicka,[...]. Cancer Res 2006
900
18


PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination.
Helen E Bryant, Eva Petermann, Niklas Schultz, Ann-Sofie Jemth, Olga Loseva, Natalia Issaeva, Fredrik Johansson, Serena Fernandez, Peter McGlynn, Thomas Helleday. EMBO J 2009
421
18

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
18

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
Barbara Norquist, Kaitlyn A Wurz, Christopher C Pennil, Rochelle Garcia, Jenny Gross, Wataru Sakai, Beth Y Karlan, Toshiyasu Taniguchi, Elizabeth M Swisher. J Clin Oncol 2011
405
18


The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
Victoria J Weston, Ceri E Oldreive, Anna Skowronska, David G Oscier, Guy Pratt, Martin J S Dyer, Graeme Smith, Judy E Powell, Zbigniew Rudzki, Pamela Kearns,[...]. Blood 2010
227
18

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Lenka Oplustilova, Kamila Wolanin, Martin Mistrik, Gabriela Korinkova, Dana Simkova, Jan Bouchal, Rene Lenobel, Jirina Bartkova, Alan Lau, Mark J O'Connor,[...]. Cell Cycle 2012
115
18

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.
Anand G Patel, Silvana B De Lorenzo, Karen S Flatten, Guy G Poirier, Scott H Kaufmann. Clin Cancer Res 2012
159
18

Resistance to PARP-Inhibitors in Cancer Therapy.
Alicia Montoni, Mihaela Robu, Emilie Pouliot, Girish M Shah. Front Pharmacol 2013
73
18


Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression.
Christian Boehler, Laurent R Gauthier, Oliver Mortusewicz, Denis S Biard, Jean-Michel Saliou, Anne Bresson, Sarah Sanglier-Cianferani, Susan Smith, Valérie Schreiber, François Boussin,[...]. Proc Natl Acad Sci U S A 2011
193
15

Targeted therapy for cancer using PARP inhibitors.
Christopher J Lord, Alan Ashworth. Curr Opin Pharmacol 2008
212
15

The PARP superfamily.
Jean-Christophe Amé, Catherine Spenlehauer, Gilbert de Murcia. Bioessays 2004
15

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
Cherrie K Donawho, Yan Luo, Yanping Luo, Thomas D Penning, Joy L Bauch, Jennifer J Bouska, Velitchka D Bontcheva-Diaz, Bryan F Cox, Theodore L DeWeese, Larry E Dillehay,[...]. Clin Cancer Res 2007
586
15

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Junko Murai, Shar-Yin N Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H Doroshow, Yves Pommier. Mol Cancer Ther 2014
444
15

Hallmarks of 'BRCAness' in sporadic cancers.
Nicholas Turner, Andrew Tutt, Alan Ashworth. Nat Rev Cancer 2004
15

PARP-3 and APLF function together to accelerate nonhomologous end-joining.
Stuart L Rulten, Anna E O Fisher, Isabelle Robert, Maria C Zuma, Michele Rouleau, Limei Ju, Guy Poirier, Bernardo Reina-San-Martin, Keith W Caldecott. Mol Cell 2011
240
12

Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate.
Cecilia E Ström, Fredrik Johansson, Mathias Uhlén, Cristina Al-Khalili Szigyarto, Klaus Erixon, Thomas Helleday. Nucleic Acids Res 2011
201
12

Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes.
Jean-Philippe Gagné, Maxim Isabelle, Ken Sin Lo, Sylvie Bourassa, Michael J Hendzel, Valina L Dawson, Ted M Dawson, Guy G Poirier. Nucleic Acids Res 2008
280
12

Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.
Niklas Schultz, Elena Lopez, Nasrollah Saleh-Gohari, Thomas Helleday. Nucleic Acids Res 2003
232
12

PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways.
Minli Wang, Weizhong Wu, Wenqi Wu, Bustanur Rosidi, Lihua Zhang, Huichen Wang, George Iliakis. Nucleic Acids Res 2006
550
12


Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal.
Mi Young Kim, Tong Zhang, W Lee Kraus. Genes Dev 2005
615
12

Iniparib plus chemotherapy in metastatic triple-negative breast cancer.
Joyce O'Shaughnessy, Cynthia Osborne, John E Pippen, Mark Yoffe, Debra Patt, Christine Rocha, Ingrid Chou Koo, Barry M Sherman, Charles Bradley. N Engl J Med 2011
604
12

Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
Timothy A Yap, Shahneen K Sandhu, Craig P Carden, Johann S de Bono. CA Cancer J Clin 2011
147
12

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Xuesong Liu, Yan Shi, David X Maag, Joann P Palma, Melanie J Patterson, Paul A Ellis, Bruce W Surber, Damien B Ready, Niru B Soni, Uri S Ladror,[...]. Clin Cancer Res 2012
131
12

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
Ruth Plummer, Christopher Jones, Mark Middleton, Richard Wilson, Jeffrey Evans, Anna Olsen, Nicola Curtin, Alan Boddy, Peter McHugh, David Newell,[...]. Clin Cancer Res 2008
283
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.